/

HBP.TO

HELIX BIOPHARMA CORPClosed

0.9200−0.04 −4.17%CAD

Toronto · as of Oct 14, 14:17 ET · 15m delay

Open

0.9200

Prev close

0.9600

Day range

0.91000.9200

52-week range

0.85003.00

Volume

4.29K0.61×

Mkt cap

70.27M

P/E ttm

—

Fwd P/E

-8.36

EPS ttm

-0.0400

Div yield

0.00%

Earnings

—

From 52w high

−69.33%

Price Chart

Yahoo Finance · delayed

HBP.TOOct 14, 2026O 0.9200H 0.9200L 0.9100C 0.9200−0.0400 (−4.17%)Vol 4.29K

SMA 501.4970
SMA 2001.7191

1Y change −61.67% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

HBP.TO HELIX BIOPHARMA CORP · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.22%
1 month: −34.29%
3 months: −34.29%
6 months: −53.77%
Year to date: −61.18%
1 year: −66.55%

Valuation & ownership

Market cap: 70.27M
Enterprise value: 70.84M
P/E (ttm): —
Forward P/E: -8.36
PEG ratio: —
Price / book: 4.79
Price / sales (ttm): —
EV / EBITDA: -21.76
EPS (ttm): -0.0400
EPS (forward): -0.1100
Beta (5y monthly): -0.14
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 76.38M
Float: 46.72M
Short % of float: 0.00%
Short ratio (days): 0.10
Held by insiders: 28.95%
Held by institutions: 0.00%
Avg volume (3m): 7.08K
50-day average: 1.51
200-day average: 1.73
52-week change: −66.55%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 31.2
vs 50-day SMA: −38.54%
vs 200-day SMA: −46.48%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 10.38%
Realised vol (20d, ann.): 113.8%
From 52-week high: −69.33%
From 52-week low: +8.24%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About HELIX BIOPHARMA CORP

Yahoo Finance profile

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Vancouver, BC, Canada
Website: helixbiopharma.com
Officers: Dr. Thomas Mehrling M.D., Ph.D. CEO & Director
Mr. Rohit Babbar C.A., CPA

SEAS

Seasonality · HBP.TO

2007–2026 · monthly returns

Strongest month Dec +7.29%Weakest month Oct −4.03%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-14.3	-3.0	-5.6	6.5	-17.7	-11.0	3.4	28.7	-52.8	1.1			−61.2%
2025	3.4	6.5	-18.4	20.0	-4.2	1.1	15.1	27.1	24.3	18.3	16.0	2.2	+166.3%
2024	-9.5	0.0	-5.3	22.2	-4.5	14.3	-4.2	9.6	-5.6	-31.1	6.1	2.3	−15.2%
2023	0.0	-13.6	15.8	-4.5	0.0	0.0	0.0	14.3	-8.3	0.0	4.5	-8.7	−4.5%
2022	-13.3	-3.8	-8.0	-17.4	0.0	31.6	-24.0	0.0	31.6	-12.0	-4.5	4.8	−26.7%
2021	94.0	-20.6	10.4	0.0	12.9	-14.6	1.2	-3.6	-28.8	-10.5	-9.8	-34.8	−40.0%
2020	-6.7	22.4	3.3	1.3	-39.4	-17.5	-32.5	-7.4	-22.0	-17.9	0.0	56.2	−62.7%
2019	18.9	-17.5	-9.6	10.6	-28.8	-27.0	107.4	42.9	51.3	-2.5	-5.1	19.6	+152.8%
2018	-12.8	9.8	0.0	-11.1	-6.3	20.0	-22.2	1.4	5.6	-33.3	-6.0	12.8	−43.6%
2017	-3.2	-10.7	-18.8	-21.3	17.6	-5.0	-5.3	0.0	0.0	-6.7	0.0	11.9	−39.0%
2016	-7.5	2.2	-2.1	8.1	0.0	0.0	0.0	-6.5	-11.2	-9.6	3.3	-0.6	−23.0%
2015	-16.7	-8.7	38.7	3.7	1.5	0.0	0.5	6.0	-5.2	5.9	-3.7	-2.9	+11.1%
2014	4.2	0.0	0.0	28.7	-8.3	13.6	-3.5	0.5	-10.3	-5.7	9.1	0.0	+25.0%
2013	-16.1	20.2	-16.0	-10.0	22.2	-10.9	6.1	8.7	31.0	-9.5	15.7	-7.1	+22.0%
2012	-5.8	10.1	-15.2	1.8	-5.9	-20.6	-3.9	-18.0	-40.0	55.0	29.0	-1.7	−37.9%
2011	10.9	6.7	8.6	-9.1	1.0	-5.6	1.4	-20.7	-13.5	4.5	-22.6	18.0	−26.1%
2010	-14.0	1.4	-1.8	-14.5	4.3	-2.0	0.0	0.0	5.4	0.4	4.3	-3.0	−19.9%
2009	-10.5	-7.1	-1.9	-14.2	3.8	9.4	41.7	7.5	36.5	-25.8	23.2	11.8	+68.9%
2008	-13.6	-5.3	-7.8	-10.2	-12.1	0.0	13.0	-9.5	1.5	-6.6	7.9	38.7	−13.6%
2007	-3.2	0.0	-7.8	-33.9	46.8	9.4	-17.1	-1.4	6.3	10.5	10.1	18.9	+18.9%

HBP.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

HBP.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HELIX BIOPHARMA CORP

Seasonality · HBP.TO

Insider Activity · HBP.TO

Congress Trades · HBP.TO

Investors Holding HBP.TO

Investors Holding HBP.TO

Congress Trades · HBP.TO

Insider Activity · HBP.TO

Seasonality · HBP.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HELIX BIOPHARMA CORP

Earnings & Dividends

News